This research not only offers preclinical evidence that supports the use of ADQ to inhibit lung metastasis in breast cancer but also reveals new perspectives on the TAM/CXCL1/NF-κB/FOXP3 signaling pathway as a viable target for Treg modulation and the immunotherapy of breast cancer. This evidence concerns the gene FOXP3 and breast cancer.